Board of Directors
Dr. Goodman is a Managing Partner at venBio Partners. He is a scientist, entrepreneur, educator, and corporate executive. He was formerly President of Pfizer’s Biotherapeutics and Bioinnovation Center, and a member of Pfizer’s Executive Leadership Team, where he oversaw the discovery and development of biotherapeutics as well as innovative new technologies. Dr. Goodman co-founded Exelixis, Renovis, Second Genome, and Ossianix prior to joining venBio. He was CEO of Renovis as a private and public company, until its acquisition by Evotec A.G. As a result of the acquisition, Dr. Goodman served on the Evotec (XETRA: EVT) Supervisory Board from 2008 until 2009. He is former professor at Stanford University and University of California Berkeley, co-founder of Berkeley’s Wills Neuroscience Institute, Investigator with the Howard Hughes Medical Institute, and currently is Adjunct Professor at UC San Francisco and UC Berkeley. Dr. Goodman is an elected member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. His honors include, amongst others, the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March of Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Dawson Prize in Genetics. Dr. Goodman is Council Chair of the California Council on Science and Technology. In addition, Dr. Goodman is currently Chair of the Board of Alexo Therapeutics, Solstice Biologics, Heart Metabolics, Second Genome, and Adheren. He is a member of the board of Checkmate Pharmaceuticals. Dr. Goodman founded Labrys Biologics and was Chair of the Board up until its acquisition by Teva Pharmaceuticals.
Dr. Adelman is a Managing Partner at venBio Partners. Dr. Adelman has a 30-year history of founding, investing in, and managing companies in the life sciences sector. Dr. Adelman received his undergraduate degree from University of California at Berkeley, his medical degree from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey. Before founding venBio, Dr. Adelman had a seven-year tenure as a Private Equity Partner at OrbiMed Advisors. There he was part of a team that invested $1.1B in both private and public companies across three venture capital funds. Dr. Adelman has co-founded a number of biotechnology companies. Dr. Adelman led venBio’s investment into Aragon Pharmaceuticals where he was a member of the Board of Directors until the company’s acquisition by Johnson & Johnson. He also led venBio’s investment into Seragon Pharmaceuticals where he was a member of the Board of Directors until the company’s acquisition by Genentech/Roche. Dr. Adelman is a member of the Board of Directors of Solstice Biologics, Heart Metabolics, Metacrine, and Precision Biosciences.
Mr. Lettmann is a Partner of Lightstone Ventures as well as a Partner on the Life Science team at Morgenthaler Ventures. Jason invests in biopharmaceutical and medical device companies and brings over 15 years of operating and venture experience in the life science sector. Jason currently serves on the Board of Directors of Alexo Therapeutics, FIRE1, Promedior, Ra Pharmaceuticals, Relievant Medsystems, Second Genome, Spinewave and Vapotherm. Jason also recently established Lightstone’s Europe office in Dublin, Ireland, to expand the firm’s investment activities to Europe. Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences and was involved with the founding of Zyga Technologies. Jason has an MBA with distinction from the University of Michigan’s Ross School of Business and a B.A. with honors from the University of Iowa.
Dr. Pons is President, Chief Executive Officer and co-founder of Alexo Therapeutics. Formerly, Dr. Pons served as Chief Scientific Officer and site head of Rinat (Pfizer), where he was responsible for portfolio delivery from idea to clinical development. He implemented the vision of a company unit following biology across therapeutic areas while generating advanced antibody technologies and turned Rinat into the center of cancer immunology for Pfizer. Dr. Pons is an inventor of three antibodies in late-stage clinical development and has advanced nine additional antibodies into human trials in multiple therapeutic areas. As Senior Vice President of R&D, he was a member of Pfizer’s World R&D Leadership Team. Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron. Dr. Pons earned his Ph.D. in molecular and cell biology at the Institute on Fundamental Biology, Barcelona, Spain and an M.S. in biotechnology and B.S. in biochemistry from Autonoma University of Barcelona. He conducted his postdoctoral studies in antibody engineering at the University of California, Berkeley.
Dr. Garcia is a leading scientist studying the structural biology of immune receptor recognition and activation and receptor signaling mechanisms using protein engineering. Dr. Garcia’s laboratory has a longstanding interest in the structural biology of adaptive immunity and is mainly focused on understanding how the T cell receptor recognizes MHC molecules. Dr. Garcia was elected to the National Academy of Sciences in 2012. Since 1999, he has been a Professor in the Department of Molecular and Cellular Physiology and Department of Structural Biology at Stanford University School of Medicine. In addition, Dr. Garcia is an Investigator with the Howard Hughes Medical Institute. Dr. Garcia is one of the inventors who discovered soluble versions of the signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα, which has provided the founding technology for Alexo Therapeutics.
A Forbes 30 under 30 star and partner at The Longevity Fund, Ms. Deming has wanted to cure aging since the age of 8. After years working on nematode longevity at UCSF, Ms. Deming matriculated at MIT at 14 to work on artificial organogenesis and bone aging. At 17, she was one of the youngest 20 under 20 fellows awarded $100,000 by Peter Thiel to pursue her venture full time. Ms. Deming is currently a full-time partner at The Longevity Fund, an early stage venture capital fund backing companies which target the aging process to treat disease, with investments in gene editing, small molecule therapeutics, and novel methods to treat disease.